On October 3, 2022 Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody drug conjugate (ADC)-based therapies, reported that global oncology leader, Genmab has licensed a novel antibody related to one of OBT’s IO programs (Press release, Oxford BioTherapeutics, OCT 3, 2022, View Source [SID1234621655]). The target was discovered using Oxford BioTherapeutics’ proprietary OGAP drug discovery platform, which incorporates one of the world’s largest proteomic databases, integrating clinical, experimental and expression data.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Genmab will be responsible for the future development and commercialization of any products incorporating this antibody. In addition to the upfront payment, OBT will receive additional development and regulatory milestone payments as well as royalties on any future product sales. This represents the first major license agreement for OBT’s IO programs to a world leader in the field of antibody-based oncology medicines.

"We are pleased to license one of our leading immuno-oncology assets to a world leading biotechnology company like Genmab, who have a wealth of internationally renowned expertise in the fields of antibody development and oncology," said Christian Rohlff, PhD, Chief Executive Officer (CEO) of Oxford BioTherapeutics. "This licensing deal enables OBT to add further depth and momentum into its drug pipeline by having this innovative asset developed by a partner."